A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients (SuparSDRF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01468493 |
Recruitment Status
:
Recruiting
First Posted
: November 9, 2011
Last Update Posted
: April 24, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
FSGS |
Study Type : | Observational |
Estimated Enrollment : | 90 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Prospective Controlled Follow-up of Serum Soluble Urokinase Receptor in the Cyclosporine A-treated Patients With Steroid-dependent and Steroid-resistant Focal Segmental Glomerulosclerosis |
Study Start Date : | January 2011 |
Estimated Primary Completion Date : | January 2019 |
Estimated Study Completion Date : | January 2019 |

Group/Cohort |
---|
steroid-sensitive FSGS |
steroid-dependent and resistant FSGS |
Healthy volunteers |
- serum suPAR level when proteinuria reduction >=50% or complete remission [ Time Frame: 6 months after steriod alone or CsA plus steriod treatment ]serum suPAR level when proteinuria reduction of >=50% or complete remission occurs within <=6 months of steroid alone or CsA plus steroid treatment
- serum suPAR level after 6 months of steroid or CsA treatment without remission [ Time Frame: 6 months after steroid alone or CsA plus steroid treatment ]serum suPAR level after 6 months of steroid alone or CsA plus steroid treatment without remission

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 14 Years to 70 Years (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Age at entry is between 14 and 70 years
- biopsy-proven primary FSGS
- proteinuria >=3 g/day
- without corticosteroids or CsA treatment before entry
Exclusion Criteria:
- Chronic Inflammatory Diseases
- malignant tumor
- diabetes mellitus
- contraindications for the treatment of corticosteroids or CsA treatment
- untolerate to or unwilling to accept corticosteroids or CsA treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01468493
Contact: Wei Shi, MD,PhD | 86-20-8385-0849 | weishi_gz@126.com |
China, Guangdong | |
Nephrology Dept.,Guangdong General Hospital | Recruiting |
Guangzhou, Guangdong, China, 510080 | |
Contact: Wei Shi, MD,PhD 86-20-8385-0849 weishi_gz@126.com | |
Sub-Investigator: Bin Zhang, MD,PhD | |
Sub-Investigator: Ruizhao Li, MD |
Principal Investigator: | Wei Shi, MD,PhD | Nephrology Dept.,Guangdong General Hospital |
Responsible Party: | Wei Shi, Director of renal division of Guangdong General Hospital, Guangdong General Hospital |
ClinicalTrials.gov Identifier: | NCT01468493 History of Changes |
Other Study ID Numbers: |
GGH-1-1 |
First Posted: | November 9, 2011 Key Record Dates |
Last Update Posted: | April 24, 2017 |
Last Verified: | April 2017 |
Keywords provided by Wei Shi, Guangdong General Hospital:
FSGS suPAR |
Additional relevant MeSH terms:
Glomerulosclerosis, Focal Segmental Glomerulonephritis Nephritis Kidney Diseases Urologic Diseases |